DiaMedica Therapeutics (NASDAQ:DMAC) Trading Down 1.5% - Here's Why

DiaMedica Therapeutics Inc. (NASDAQ:DMAC - Get Free Report) shares traded down 1.5% during mid-day trading on Friday . The company traded as low as $5.60 and last traded at $5.76. 53,263 shares were traded during trading, a decline of 35% from the average session volume of 81,698 shares. The stock had previously closed at $5.85.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $7.00 price objective on shares of DiaMedica Therapeutics in a research note on Friday, November 15th.

DiaMedica Therapeutics Stock Up 1.4 %

The stock has a 50-day moving average of $5.51 and a 200 day moving average of $4.56. The stock has a market cap of $255.70 million, a PE ratio of -10.68 and a beta of 1.46.

Institutional Trading of DiaMedica Therapeutics

Institutional investors have recently bought and sold shares of the business. Blue Trust Inc. purchased a new stake in shares of DiaMedica Therapeutics during the third quarter worth about $185,000. Geode Capital Management LLC increased its stake in DiaMedica Therapeutics by 29.6% during the 3rd quarter. Geode Capital Management LLC now owns 306,958 shares of the company's stock worth $1,286,000 after buying an additional 70,070 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of DiaMedica Therapeutics during the third quarter valued at approximately $40,000. Finally, Y Intercept Hong Kong Ltd purchased a new position in shares of DiaMedica Therapeutics in the fourth quarter valued at approximately $81,000. 10.12% of the stock is owned by institutional investors and hedge funds.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.